Equidyne upbraids Rosch for INJEX claims:
This article was originally published in Clinica
Equidyne of San Diego, US, has responded to an announcement by Rosch Medizintechnik (Frankfurt, Germany) regarding the INJEX reusable needle-free injection system. Rosch said that it had received US FDA 510(k) approval for the system and would be able to market it in the US. Equidyne says that it owns all US patents covering the INJEX technology and that Rosch, which has European marketing rights, has no US marketing rights other than for INJEX growth hormone. Rosch, which was spun out of Equidyne in 2000, sold exclusive worldwide distribution rights to INJEX for the delivery of hormone deficiency products to an unnamed pharmaceutical company in March, which entailed a $254,000 payment to Equidyne.
You may also be interested in...
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.
Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.